Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a post-effective amendment to a Form F-1 registration statement with the SEC, enabling the sale of ordinary shares represented by depositary shares. These shares are issuable upon the exercise of previously granted warrants, including the October Private Placement Warrants, May Private Placement Warrants, Wainwright October Warrants, and Wainwright May Warrants. The company will not receive proceeds from the sale of shares by warrant holders, except for proceeds from the cash exercise of the warrants. The amendment allows selling shareholders to sell their shares on the open market, providing them with liquidity and the potential to capitalize on their investment. The registration statement includes legal terms, indemnification of directors and...Show More

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a post-effective amendment to a Form F-1 registration statement with the SEC, enabling the sale of ordinary shares represented by depositary shares. These shares are issuable upon the exercise of previously granted warrants, including the October Private Placement Warrants, May Private Placement Warrants, Wainwright October Warrants, and Wainwright May Warrants. The company will not receive proceeds from the sale of shares by warrant holders, except for proceeds from the cash exercise of the warrants. The amendment allows selling shareholders to sell their shares on the open market, providing them with liquidity and the potential to capitalize on their investment. The registration statement includes legal terms, indemnification of directors and officers, and details of recent unregistered securities sales. Biodexa Pharmaceuticals has appointed Donald J. Puglisi as the authorized agent for process service in the United States, facilitating legal actions if necessary. The company's shares are subject to UK law, and the amendment outlines the jurisdiction for potential legal disputes, which is primarily in New York courts. The amendment also includes a jury trial waiver, limiting the legal recourse for shareholders. The company's financial statements and other required information will be updated and incorporated by reference from SEC filings, ensuring investors have access to the latest financial data.